• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

1,129
108
74
70
68

COUNTRY

69
22
16
10
9

CATEGORIES

  • 574
  • 118
  • 550
  • 75
  • 526
  • 43
  • 505
  • 18
  • 18
  • 23

PRICE

869
1,164
1,600
2,946

PUBLISHED

153
249
685
2,946

PRODUCT TYPE

2,375
494
67
7
1
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
Apoptosis in Oncology Drug Pipeline Update 2014 Apoptosis in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Apoptosis in Oncology Drug Pipeline Update 2014

Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis...

July 2014
FROM
Epigenetic Therapy in Oncology Drug Pipeline Update 2014 Epigenetic Therapy in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Epigenetic Therapy in Oncology Drug Pipeline Update 2014

Improper gene activation or silencing by loss of epigenetic control can lead to aberrant gene expression that can drive the development of diseases such as cancer, autoimmunity, diabetes, or neurological...

July 2014
FROM
Calcium Signaling Pathway in Cancer Drug Pipeline Update 2014 Calcium Signaling Pathway in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Calcium Signaling Pathway in Cancer Drug Pipeline Update 2014

There are today 168 companies plus partners developing 222 calcium signaling pathway targeting drugs in 838 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated...

July 2014
FROM
TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

The TGF-beta receptor signaling pathway activates the MAPK/SMAD signaling modules. There are today 287 companies plus partners developing 411 TGF-beta receptor pathway targeting drugs in 1411 developmental...

July 2014
FROM
Jak-STAT Signaling Pathway in Oncology Drug Pipeline Update 2014 Jak-STAT Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Jak-STAT Signaling Pathway in Oncology Drug Pipeline Update 2014

The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis...

July 2014
FROM
EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2014 EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2014

The EGFR1 signaling pathway activates the Ras/Raf/MAPK signaling modules. There are today 371 companies plus partners developing 642 EGFR1 pathway targeting drugs in 2397 developmental projects in cancer....

July 2014
FROM
ID Signaling Pathway in Oncology Drug Pipeline Update 2014 ID Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

ID Signaling Pathway in Oncology Drug Pipeline Update 2014

Inhibitor of DNA binding (ID) proteins are members of the helix-loop-helix (HLH) family of proteins which lack a DNA binding domain themselves but bind to other family members inhibiting their DNA binding...

July 2014
FROM
Colorectal Cancer Drug Pipeline Update 2014 Colorectal Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Colorectal Cancer Drug Pipeline Update 2014

Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of...

July 2014
FROM
Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

The androgen receptor signaling pathway activates the SMAD signaling module. There are today 332 companies plus partners developing 441 Androgen Receptor drugs in 1457 developmental projects in cancer....

July 2014
FROM
Gap Junctions in Oncology Drug Pipeline Update 2014 Gap Junctions in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Gap Junctions in Oncology Drug Pipeline Update 2014

Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels',...

July 2014
FROM
GnRH Signaling Pathway in Oncology Drug Pipeline Update 2014 GnRH Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

GnRH Signaling Pathway in Oncology Drug Pipeline Update 2014

Gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus acts upon its receptor in the anterior pituitary to regulate the production and release of the gonadotropins, LH and FSH. There...

July 2014
FROM
TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014 TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014

The TNF-alfa signaling pathway stimulates the MAPK signaling module and activates NFkB. There are today 366 companies plus partners developing 550 TNF-alpha pathway targeting drugs in 2048 developmental...

July 2014
FROM
FSH Signaling Pathway in Oncology Drug Pipeline Update 2014 FSH Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

FSH Signaling Pathway in Oncology Drug Pipeline Update 2014

Follicle stimulating hormone (FSH) binds to FSH-receptor which is coupled to Gs protein that in turn activates cAMP dependent protein kinases (PKA) and thus triggers FSH signaling which continues further...

July 2014
FROM
p53 Signaling Pathway in Cancer Drug Pipeline Update 2014 p53 Signaling Pathway in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

p53 Signaling Pathway in Cancer Drug Pipeline Update 2014

p53 activation is induced by a number of stress signals, including DNA damage, oxidative stress and activated oncogenes. The p53 protein is employed as a transcriptional activator of p53-regulated genes....

July 2014
FROM
ErbB Signaling Pathway in Cancer Drug Pipeline Update 2014 ErbB Signaling Pathway in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

ErbB Signaling Pathway in Cancer Drug Pipeline Update 2014

The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation,...

July 2014
FROM
Mitochondrial Drugs in Oncology Drug Pipeline Update 2014 Mitochondrial Drugs in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Mitochondrial Drugs in Oncology Drug Pipeline Update 2014

Focusing on mitochondria has recently become an intriguing target for cancer therapy. It is well known that mitochondrial activity in tumor cells is suppressed and exploiting the differences in mitochondrial...

July 2014
FROM
Head and Neck Cancer Drug Pathway Analyzer 2014 Head and Neck Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Head and Neck Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 149 targeted molecular therapies known to affect more than 241 specific intracellular signaling pathways...

July 2014
FROM
Breast Cancer Drug Pathway Analyzer 2014 Breast Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Breast Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 532 targeted molecular therapies known to affect more than 253 specific intracellular signaling pathways...

July 2014
FROM
Conjugated Drugs in Oncology: Drug Pathway Analyzer 2014 Conjugated Drugs in Oncology: Drug Pathway Analyzer 2014 - Product Thumbnail Image

Conjugated Drugs in Oncology: Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 262 conjugated drugs known to affect more than 206 specific intracellular signaling pathways for the...

July 2014
FROM
Transcriptional Misregulation in Cancer Drug Pipeline Update 2014 Transcriptional Misregulation in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Transcriptional Misregulation in Cancer Drug Pipeline Update 2014

There are today 222 companies plus partners developing 297 transcriptional misregulation targeting drugs in 1186 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated...

July 2014
FROM
Loading Indicator

Our Clients

Our clients' logos